Evidence map›Paper›PMID 33758617›Full record

ArticleJournal of Cancer2021

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression.

Hangyu Zhang, Changgang Liu, Xinbo Wang, Yongfang Wang, Jie Zheng

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Decreased expression ofFrontiers in oncology · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hangyu ZhangDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.
Changgang LiuDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.
Xinbo WangDepartment of Surgical Oncology, Weifang People's Hospital, Weifang Medical University, Shandong Province, China.
Yongfang WangDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.
Jie ZhengDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scavenger receptor class A member 5 (SCARA5) has been reported to be implicated in several types of cancer. However, its biological roles and mechanism of SCARA5 in gastric cancer (GC) have not been elucidated. In the present study, SCARA5 expression was found to be downregulated in GC which was associated with promoter methylation. The protein level of SCARA5 was negatively associated with aggressive clinicopathological characteristics, as well as poor prognosis. Moreover, SCARA5 overexpression markedly suppressed the growth, migration and invasion of GC cell lines

Indexed as

EMTGastric cancermigration and invasionproliferationSCARA5

Identifiers

PMID33758617
PMCPMC7974898
OpenAlexW3139463562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.